Home › Research › Treatments
Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy
Finali G, Piccirilli M, Oliani C, Piccinin GL.. Italian journal of neurological sciences, 1992-03-01
Topic: Amyloid, tau and blood-test diagnosis
In a double blind randomized crossover trial lasting 6 months selegiline, a selective MAO-B inhibitor, was tested against placebo for activity on verbal memory performances in Alzheimer-type dementia (DAT). Verbal memory was assessed with the Rey-Auditory-Verbal Learning Test at the start of treatment, at the time scheduled for crossover (90 days) and at the end of the trial (180 days). The results suggest that selegiline possesses significant activity on some memory parameters, which seems to depend on an improvement both in information processing abilities and in learning strategies at the moment of acquisition.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Finali, G., Piccirilli, M., Oliani, C., & Piccinin, G. L. (1992). Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy. Italian journal of neurological sciences. https://doi.org/10.1007/bf02226963
Vancouver
Finali G, Piccirilli M, Oliani C, Piccinin GL. Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy. Italian journal of neurological sciences. 1992. doi:10.1007/bf02226963. PMID: 1592575.
BibTeX
@article{finali1992-1592575,
author = {Finali, G. and Piccirilli, M. and Oliani, C. and Piccinin, G. L.},
title = {{Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy}},
journal = {Italian journal of neurological sciences},
year = {1992},
doi = {10.1007/bf02226963},
pmid = {1592575},
url = {https://doi.org/10.1007/bf02226963}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The results suggest that selegiline possesses significant activity on some memory parameters, which seems to depend on an improvement both in information processing abilities and in learning strategies at the moment of acquisition.
Why it matters
In a six-month double-blind crossover trial, selegiline showed significant activity on some verbal memory measures in people with Alzheimer-type dementia. The authors suggest this may reflect improved information processing and learning strategies during acquisition.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 49/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for sample size and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Italian journal of neurological sciences) |
| Journal's citation record | 1 / 4 | Neurological Sciences: journal h-index 113 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1992 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomised / blinded | 2 / 2 | Randomised and blinded or placebo-controlled (as stated in the record) |
| Times cited | 3 / 7 | Cited 18 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 36 year(s) since 1992 |
| Impact for its field and year | 2 / 6 | Cited 1.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Gian Luigi Piccinin: h-index 11 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Perugia: institution h-index 747 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 1592575) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.